- Correction
- Open access
- Published:
Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
BMC Health Services Research volume 19, Article number: 972 (2019)
The Original Article was published on 12 November 2019
Correction to: BMC Health Serv Res
https://0-doi-org.brum.beds.ac.uk/10.1186/s12913-019-4680-2
In the original publication of this article [1], there is a mistake in the Fig. 2a, b, and c. The mistake is in the very last column where it shows TOTAL. The updated Fig. 2 is shown below. Additionally, a footnote “Total is based on the average discounted price amongst all provinces.” should be added to Table 2 and Additional files 1, 2, and 3.
a. Overall units purchased of insulin glargine by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Basaglar® were purchased instead of the originator drug Lantus®. b Overall units purchased of filgrastim by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Grastofil® were purchased instead of the originator drug Neupogen®. c Overall units purchased of infliximab by province. All dollar figures are in Canadian dollars. BC=British Columbia, AB = Alberta, SK=Saskatchewan, MB = Manitoba, ON=Ontario, QC = Quebec, NB=New Brunswick, NS=Nova Scotia, PEI/NL = Prince Edward Island / Newfoundland. Potential Savings represents the potential savings that could have been realized if the biosimilar drug Inflectra® were purchased instead of the originator drug Remicade®
Reference
Mansell K, et al. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. BMC Health Serv Res. 2019;19:827.
Author information
Authors and Affiliations
Additional information
The original article can be found online at https://0-doi-org.brum.beds.ac.uk/10.1186/s12913-019-4680-2
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Mansell, K., Bhimji, H., Eurich, D. et al. Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. BMC Health Serv Res 19, 972 (2019). https://0-doi-org.brum.beds.ac.uk/10.1186/s12913-019-4829-z
Published:
DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12913-019-4829-z